Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kleb4V + AS03 is a tetravalent bioconjugate vaccine candidate targeting Klebsiella pneumoniae. It contains O antigen-polysaccharides from the most predominant K. pneumoniae serotypes (O1, O2 including O2a and O2afg subtypes, and O3b) formulated with the AS03 adjuvant system. AS03 is a squalene-based immunologic adjuvant that contains 10.69 mg squalene, 11.86 mg DL-α-tocopherol, and 4.86 mg polysorbate 80. The vaccine is designed to enhance immune response against K. pneumoniae, a Gram-negative pathogen that can cause serious urinary and blood infections and pneumonia, and is a major public health threat due to its antibiotic resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kleb4V + AS03.